New alpha blockers to treat male lower urinary tract symptoms

Eu Chang Hwang, Shreyas Gandhi, Jae H. Jung

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Purpose of review To date it is unclear whether the selectivity of new alpha-blockers to alpha-adrenergic receptor subtypes translates into more clinical benefits and less adverse effects in clinical practice. We performed a systematic review of the two new Abs silodosin and naftopidil. With the availability of numerous alpha-blockers to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia, the findings of this review will be highly relevant to the field of urology. Recent findings Silodosin was found to be more effective than placebo in improving International Prostate Symptom Score (IPSS) and quality of life scores and as effective as other alpha-blockers. Although the incidence of cardiovascular adverse events of silodosin was similar compared with placebo and other alpha-blockers (tamsulosin, naftopidil, alfuzosin), the sexual adverse events were more common with silodosin. No placebo-controlled randomized trial exists investigating the effects of naftopidil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Naftopidil had similar efficacy with regards to IPSS and quality of life compared with tamsulosin. The rate of adverse events was similar compared with tamsulosin. Summary The two new selective alpha-blockers, silodosin, and naftopidil showed similar efficacy in IPSS and quality of life compared with other alpha-blockers. However, silodosin has more sexual adverse events.

Original languageEnglish
Pages (from-to)273-276
Number of pages4
JournalCurrent Opinion in Urology
Volume28
Issue number3
DOIs
Publication statusPublished - 2018 May 1

Fingerprint

Lower Urinary Tract Symptoms
tamsulosin
Prostate
Placebos
Quality of Life
Prostatic Hyperplasia
Receptors, Adrenergic, alpha
Urology
silodosin
Randomized Controlled Trials
naftopidil
Incidence

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Hwang, Eu Chang ; Gandhi, Shreyas ; Jung, Jae H. / New alpha blockers to treat male lower urinary tract symptoms. In: Current Opinion in Urology. 2018 ; Vol. 28, No. 3. pp. 273-276.
@article{4d6511c3b63a4569be4b7747489bf681,
title = "New alpha blockers to treat male lower urinary tract symptoms",
abstract = "Purpose of review To date it is unclear whether the selectivity of new alpha-blockers to alpha-adrenergic receptor subtypes translates into more clinical benefits and less adverse effects in clinical practice. We performed a systematic review of the two new Abs silodosin and naftopidil. With the availability of numerous alpha-blockers to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia, the findings of this review will be highly relevant to the field of urology. Recent findings Silodosin was found to be more effective than placebo in improving International Prostate Symptom Score (IPSS) and quality of life scores and as effective as other alpha-blockers. Although the incidence of cardiovascular adverse events of silodosin was similar compared with placebo and other alpha-blockers (tamsulosin, naftopidil, alfuzosin), the sexual adverse events were more common with silodosin. No placebo-controlled randomized trial exists investigating the effects of naftopidil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Naftopidil had similar efficacy with regards to IPSS and quality of life compared with tamsulosin. The rate of adverse events was similar compared with tamsulosin. Summary The two new selective alpha-blockers, silodosin, and naftopidil showed similar efficacy in IPSS and quality of life compared with other alpha-blockers. However, silodosin has more sexual adverse events.",
author = "Hwang, {Eu Chang} and Shreyas Gandhi and Jung, {Jae H.}",
year = "2018",
month = "5",
day = "1",
doi = "10.1097/MOU.0000000000000488",
language = "English",
volume = "28",
pages = "273--276",
journal = "Current Opinion in Urology",
issn = "0963-0643",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

New alpha blockers to treat male lower urinary tract symptoms. / Hwang, Eu Chang; Gandhi, Shreyas; Jung, Jae H.

In: Current Opinion in Urology, Vol. 28, No. 3, 01.05.2018, p. 273-276.

Research output: Contribution to journalReview article

TY - JOUR

T1 - New alpha blockers to treat male lower urinary tract symptoms

AU - Hwang, Eu Chang

AU - Gandhi, Shreyas

AU - Jung, Jae H.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Purpose of review To date it is unclear whether the selectivity of new alpha-blockers to alpha-adrenergic receptor subtypes translates into more clinical benefits and less adverse effects in clinical practice. We performed a systematic review of the two new Abs silodosin and naftopidil. With the availability of numerous alpha-blockers to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia, the findings of this review will be highly relevant to the field of urology. Recent findings Silodosin was found to be more effective than placebo in improving International Prostate Symptom Score (IPSS) and quality of life scores and as effective as other alpha-blockers. Although the incidence of cardiovascular adverse events of silodosin was similar compared with placebo and other alpha-blockers (tamsulosin, naftopidil, alfuzosin), the sexual adverse events were more common with silodosin. No placebo-controlled randomized trial exists investigating the effects of naftopidil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Naftopidil had similar efficacy with regards to IPSS and quality of life compared with tamsulosin. The rate of adverse events was similar compared with tamsulosin. Summary The two new selective alpha-blockers, silodosin, and naftopidil showed similar efficacy in IPSS and quality of life compared with other alpha-blockers. However, silodosin has more sexual adverse events.

AB - Purpose of review To date it is unclear whether the selectivity of new alpha-blockers to alpha-adrenergic receptor subtypes translates into more clinical benefits and less adverse effects in clinical practice. We performed a systematic review of the two new Abs silodosin and naftopidil. With the availability of numerous alpha-blockers to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia, the findings of this review will be highly relevant to the field of urology. Recent findings Silodosin was found to be more effective than placebo in improving International Prostate Symptom Score (IPSS) and quality of life scores and as effective as other alpha-blockers. Although the incidence of cardiovascular adverse events of silodosin was similar compared with placebo and other alpha-blockers (tamsulosin, naftopidil, alfuzosin), the sexual adverse events were more common with silodosin. No placebo-controlled randomized trial exists investigating the effects of naftopidil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Naftopidil had similar efficacy with regards to IPSS and quality of life compared with tamsulosin. The rate of adverse events was similar compared with tamsulosin. Summary The two new selective alpha-blockers, silodosin, and naftopidil showed similar efficacy in IPSS and quality of life compared with other alpha-blockers. However, silodosin has more sexual adverse events.

UR - http://www.scopus.com/inward/record.url?scp=85045224137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045224137&partnerID=8YFLogxK

U2 - 10.1097/MOU.0000000000000488

DO - 10.1097/MOU.0000000000000488

M3 - Review article

C2 - 29613909

AN - SCOPUS:85045224137

VL - 28

SP - 273

EP - 276

JO - Current Opinion in Urology

JF - Current Opinion in Urology

SN - 0963-0643

IS - 3

ER -